Home
>
US Stocks
>
Ignyta, Inc.

Ignyta, Inc. (RXDX)

$198.83

+0.18

(+0.09%)▲

Market is closed - opens 7 PM, 05 Jun 2023

Insights on Ignyta, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 653.0K → 1.10M (in $), with an average increase of 40.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 11 quarters, -6.94M → -40.87M (in $), with an average decrease of 20.8% per quarter

Performance

  • $198.64
    $198.86
    $198.83
    downward going graph

    0.1%

    Downside

    Day's Volatility :0.11%

    Upside

    0.01%

    downward going graph
  • $22.31
    $198.99
    $198.83
    downward going graph

    88.78%

    Downside

    52 Weeks Volatility :88.79%

    Upside

    0.08%

    downward going graph

Returns

PeriodIgnyta, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
58.14%
0.9%
-8.3%
6 Months
427.12%
-6.8%
-6.5%
1 Year
614.96%
0.4%
-6.1%
3 Years
686.2%
27.3%
21.8%

Highlights

Market Capitalization
9.5B
Book Value
$14.62
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.54
Wall Street Target Price
195.0
Profit Margin
0.0%
Operating Margin TTM
-4064.73%
Return On Assets TTM
-20.06%
Return On Equity TTM
-33.3%
Revenue TTM
4.0M
Revenue Per Share TTM
0.09
Quarterly Revenue Growth YOY
-71.8%
Gross Profit TTM
-106.0M
EBITDA
-161.6M
Diluted Eps TTM
-3.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.9
EPS Estimate Next Year
-4.31
EPS Estimate Current Quarter
-0.91
EPS Estimate Next Quarter
-0.96

Analyst Recommendation

Hold
    46%Buy
    53%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Ignyta, Inc.(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
16
16
Hold
8
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 1.93%

Current $198.83
Target $195.00

Company Financials

FY19Y/Y Change
Revenue
1.1M
-
Net Income
-29.7M
-
Net Profit Margin
-2.7K%
-
FY20Y/Y Change
Revenue
1.2M
↑ 9.93%
Net Income
-37.1M
↑ 24.95%
Net Profit Margin
-3.0K%
↓ 363.22%
FY21Y/Y Change
Revenue
3.1M
↑ 154.6%
Net Income
-90.2M
↑ 142.86%
Net Profit Margin
-2.9K%
↑ 139.26%
FY22Y/Y Change
Revenue
6.8M
↑ 117.61%
Net Income
-141.8M
↑ 57.16%
Net Profit Margin
-2.1K%
↑ 800.72%
Q4 FY21Q/Q Change
Revenue
-295.0K
↓ 129.32%
Net Income
-29.9M
↑ 9.46%
Net Profit Margin
10.1K%
↑ 12858.69%
Q1 FY22Q/Q Change
Revenue
3.9M
↓ 1428.47%
Net Income
-32.1M
↑ 7.18%
Net Profit Margin
-818.22%
↓ 10959.91%
Q2 FY22Q/Q Change
Revenue
1.3M
↓ 67.62%
Net Income
-33.6M
↑ 4.93%
Net Profit Margin
-2.7K%
↓ 1833.24%
Q3 FY22Q/Q Change
Revenue
968.0K
↓ 23.72%
Net Income
-37.3M
↑ 10.78%
Net Profit Margin
-3.9K%
↓ 1199.26%
Q4 FY22Q/Q Change
Revenue
653.0K
↓ 32.54%
Net Income
-38.8M
↑ 3.99%
Net Profit Margin
-5.9K%
↓ 2085.57%
Q1 FY23Q/Q Change
Revenue
1.1M
↑ 69.22%
Net Income
-40.9M
↑ 5.45%
Net Profit Margin
-3.7K%
↑ 2237.1%
FY16Y/Y Change
Total Assets
144.9M
↓ 26.12%
Total Liabilities
50.1M
↓ 16.65%
FY19Y/Y Change
Total Assets
50.5M
-
Total Liabilities
87.5M
-
FY20Y/Y Change
Total Assets
59.6M
↑ 18.12%
Total Liabilities
157.2M
↑ 79.73%
FY21Y/Y Change
Total Assets
267.8M
↑ 349.08%
Total Liabilities
32.6M
↓ 79.23%
FY22Y/Y Change
Total Assets
740.8M
↑ 176.61%
Total Liabilities
64.8M
↑ 98.51%
Q4 FY21Q/Q Change
Total Assets
267.8M
↓ 7.32%
Total Liabilities
32.6M
↑ 21.64%
Q1 FY22Q/Q Change
Total Assets
253.6M
↓ 5.31%
Total Liabilities
46.9M
↑ 43.53%
Q2 FY22Q/Q Change
Total Assets
237.6M
↓ 6.31%
Total Liabilities
45.8M
↓ 2.35%
Q3 FY22Q/Q Change
Total Assets
298.6M
↑ 25.69%
Total Liabilities
66.1M
↑ 44.42%
Q4 FY22Q/Q Change
Total Assets
740.8M
↑ 148.07%
Total Liabilities
64.8M
↓ 1.93%
Q1 FY23Q/Q Change
Total Assets
758.4M
↑ 2.38%
Total Liabilities
60.8M
↓ 6.18%
FY18Y/Y Change
Operating Cash Flow
-6.1M
↓ 93.23%
Investing Cash Flow
-82.0K
-
Financing Cash Flow
10.1M
-
FY19Y/Y Change
Operating Cash Flow
-20.2M
↑ 231.15%
Investing Cash Flow
7.9M
↓ 9774.39%
Financing Cash Flow
9.8M
↓ 3.81%
FY20Y/Y Change
Operating Cash Flow
-28.0M
↑ 38.72%
Investing Cash Flow
-1.1M
↓ 113.4%
Financing Cash Flow
79.9M
↑ 718.92%
FY21Y/Y Change
Operating Cash Flow
-63.5M
↑ 126.66%
Investing Cash Flow
-1.1M
↑ 6.87%
Financing Cash Flow
267.7M
↑ 235.1%
Q4 FY21Q/Q Change
Operating Cash Flow
-22.2M
↑ 30.63%
Investing Cash Flow
-190.0K
↓ 48.09%
Financing Cash Flow
505.0K
↓ 106.37%
Q1 FY22Q/Q Change
Operating Cash Flow
-29.4M
↑ 32.52%
Investing Cash Flow
-955.0K
↑ 402.63%
Financing Cash Flow
123.0K
↓ 75.64%
Q2 FY22Q/Q Change
Operating Cash Flow
-28.8M
↓ 1.84%
Investing Cash Flow
-116.9M
↑ 12136.96%
Financing Cash Flow
14.6M
↑ 11798.37%
Q3 FY22Q/Q Change
Operating Cash Flow
-53.3M
↑ 84.71%
Investing Cash Flow
-65.8M
↓ 43.73%
Financing Cash Flow
72.2M
↑ 393.56%
Q1 FY23Q/Q Change
Operating Cash Flow
-39.5M
↓ 3.84%
Investing Cash Flow
-192.3M
-
Financing Cash Flow
52.8M
↓ 88.89%

Technicals Summary

Sell

Neutral

Buy

Ignyta, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ignyta, Inc.
Ignyta, Inc.
2.34%
427.12%
614.96%
686.2%
686.2%
Moderna, Inc.
Moderna, Inc.
0.28%
-25.82%
-4.84%
117.92%
601.67%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.87%
-2.05%
17.39%
22.45%
137.1%
Seagen, Inc.
Seagen, Inc.
-1.61%
61.18%
39.62%
26.01%
217.64%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.63%
5.09%
23.88%
20.49%
123.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ignyta, Inc.
Ignyta, Inc.
NA
NA
NA
-3.9
-0.33
-0.2
0.0
14.62
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.91
19.91
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.18
26.18
0.41
14.61
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ignyta, Inc.
Ignyta, Inc.
Hold
$9.5B
686.2%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
601.67%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$80.7B
137.1%
19.91
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
217.64%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.3B
123.04%
26.18
35.4%

Institutional Holdings

  • RTW INVESTMENTS, LLC

    6.85%

  • BlackRock Inc

    5.88%

  • Vanguard Group Inc

    5.69%

  • Boxer Capital LLC

    3.97%

  • 72 Investment Holdings, LLC

    3.87%

  • Cormorant Asset Management, LLC

    3.46%

Corporate Announcements

  • Ignyta, Inc. Earnings

    Ignyta, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company's precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is headquartered in San Diego, CA.

Organization
Ignyta, Inc.
Employees
97
CEO
Mr. Mark C. McKenna
Industry
Healthcare

Discover More

FAQs